CompletedNot Applicable

Predictive Value of Embryonic Testing

United States237 participantsStarted 2018-07-30

Plain-language summary

The primary objective of this study is to determine the predictive value of preimplantation genetic screening (PGS) as a marker of embryonic competence. Secondary objectives are to define the related or independent predictive values of other proposed markers of embryonic and maternal reproductive competence in assisted reproductive technology (ART) cycles.

Who can participate

Age range18 Years – 42 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Couples electing embryonic aneuploidy screening (PGS)
✓. Couples electing single embryo transfer

Exclusion criteria

✕. Any prior failed IVF cycle
✕. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid
✕. Diagnosis of chronic endometritis
✕. Maximum day 3 FSH level of 12 or higher
✕. Anti-mullerian hormone level less than 0.5 g/mL, tested within previous year
✕. Total basal antral follicle count less than 8 follicles
✕. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
✕. BMI \<18.5 or \> 35

What they're measuring

Predictive Value of Aneuploidy Screening

Timeframe: approximately 1 month post clinical outcome

Trial details

NCT IDNCT03604107

SponsorReproductive Medicine Associates of New Jersey

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-09-30

View on ClinicalTrials.gov More Infertility trials